García Pascual Luis, Surralles Maria Lluïsa, Morlius Xavier, Garcia Cano Laia, González Mínguez Clarisa
Servicio de Endocrinología, Hospital Universitari Mútua de Terrassa, Terrassa, España.
Servicio de Anatomía Patológica, Hospital Universitari Mútua de Terrassa, Terrassa, España.
Endocrinol Diabetes Nutr (Engl Ed). 2018 Dec;65(10):577-583. doi: 10.1016/j.endinu.2018.07.001. Epub 2018 Sep 24.
To ascertain the prevalence of Bethesda category III cytologies and their malignancy rate, and to analyze differences in the second cytology, malignancy rate, type of carcinoma, and TNM stage between the cytological atypia (CA) and architectural atypia (AA) groups.
A retrospective study of 973 biopsies. Bethesda category III cytologies were classified as CA when nuclear atypia was seen but they were not diagnostic or suspicious of malignancy, and as AA when smears had few cells but had a predominantly microfollicular pattern and minimal or absent colloid. The cytological and pathological results were correlated.
There were 87 (8.9%) Bethesda category III cytologies (34 CC, 53 AA). Second cytologies were performed in 23 patients (16 with CA, 7 with AA), and a benign result was found in 68.7% of CA and 71.4% of the AA group. Sixty-four patients (23 CA, 41 AA) underwent surgery and 15 of these (23.4%) had a malignant disease: 39.1% CA vs 14.6% AA (P=.029). There was a false negative result in the CA group. The follicular variant of papillary thyroid carcinoma was the most common malignancy (60%). There were no differences in type of carcinoma or TNM stage between CA and AA patients.
The reported prevalence of Bethesda category III cytologies was as expected. The malignancy rate was significantly higher in the CA group, but there were no differences in the result of the second cytology, type of carcinoma found, or TNM stage. The division of Bethesda category III cytologies is useful to provide a better stratification of the risk of malignancy.
确定贝塞斯达III类细胞学检查结果的患病率及其恶性率,并分析细胞学异型性(CA)组和结构异型性(AA)组在第二次细胞学检查结果、恶性率、癌的类型及TNM分期方面的差异。
对973例活检病例进行回顾性研究。当发现核异型性但不能诊断或怀疑为恶性时,贝塞斯达III类细胞学检查结果归为CA;当涂片细胞数量少但主要为微滤泡模式且胶体极少或无胶体时,归为AA。将细胞学和病理结果进行对比。
有87例(8.9%)贝塞斯达III类细胞学检查结果(34例为CA,53例为AA)。23例患者(16例CA,7例AA)进行了第二次细胞学检查,CA组68.7%和AA组71.4%的检查结果为良性。64例患者(23例CA,41例AA)接受了手术,其中15例(23.4%)患有恶性疾病:CA组为39.1%,AA组为14.6%(P = 0.029)。CA组有假阴性结果。乳头状甲状腺癌的滤泡变体是最常见的恶性肿瘤(60%)。CA组和AA组患者在癌的类型或TNM分期方面没有差异。
所报道的贝塞斯达III类细胞学检查结果的患病率符合预期。CA组的恶性率显著更高,但在第二次细胞学检查结果、所发现的癌的类型或TNM分期方面没有差异。将贝塞斯达III类细胞学检查结果进行分类有助于更好地对恶性风险进行分层。